CD274 and neoplasm: To date, PD-L1 expression seems more prognostic than predictive, while it has been recently showed that tumor mutational burden (TMB) and T-cell-inflamed gene expression profile (TcellinfGEP) are associated with the outcome of patients treated with pembrolizumab in both second-line therapy and first-line therapy for cisplatn-ineligible UC patients [16].